Cantor Fitzgerald Estimates Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Prothena in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biotechnology company will post earnings of ($3.97) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share.

Prothena (NASDAQ:PRTA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $1.22 million. During the same quarter last year, the company posted $0.38 earnings per share. Prothena’s revenue was down 98.9% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $48.00 target price (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Chardan Capital started coverage on shares of Prothena in a research note on Friday, December 20th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Prothena Stock Up 7.3 %

PRTA stock opened at $15.48 on Wednesday. The firm’s 50-day simple moving average is $14.28 and its 200 day simple moving average is $18.00. The stock has a market cap of $832.98 million, a PE ratio of -6.24 and a beta of 0.10. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $34.17.

Institutional Investors Weigh In On Prothena

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in shares of Prothena by 14.8% in the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock worth $69,911,000 after buying an additional 539,359 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Prothena by 1,122.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after purchasing an additional 483,673 shares during the period. Armistice Capital LLC grew its position in Prothena by 42.3% during the 2nd quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company’s stock worth $32,198,000 after purchasing an additional 464,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Prothena during the 4th quarter valued at $724,000. Finally, Barclays PLC lifted its holdings in shares of Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 49,916 shares in the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.